CD47 Protein, Human (HEK293, His)

Cat. No.:	HY-P7336
Synonyms:	rHuCD47, His; CD47; MER6; IAP; OA3
Species:	Human
Source:	HEK293
Accession:	Q08722/NP_942088.1 (Q19-P139)
Gene ID:	961
Molecular Weight:	30-45 kDa

PROPERTIES

AA Sequence	Q L L F N K T K S V E F T F C N D T V V I P C F V T N M E A Q N T T E V Y V K W K F K G R D I Y T F D G A L N K S T V P T D F S S A K I E V S Q L L K G D A S L K M D K S D A V S H T G N Y T C E V T E L T R E G E T I I E L K Y R V V S W F S P H H H H H H
Biological Activity	1.2 μg/mL (100 μL/well) of immoblized recombinant human CD47-His can bind human SIRPa-Fc with a linear range of 20-65 ng/mL. 2.Immobilized Human SIRPA-Fc at 10 μg/mL (100 μl/well) can bind Human CD47-His .The ED_{50} is 13.21 ng/mL 3. Immobilized Human CD47, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human SIRP alpha, hFc Tag with the EC_{50} of 46.8ng/ml determined by ELISA (QC Test). 4. Human CD47, His Tag captured on CM5 Chip via Anti-His Antibody can bind Human SIRP alpha, hFc Tag with an affinity constant of 18.9nM as determined in SPR assay (Biacore T200). 5.Measured by its binding ability in a functional ELISA. Immobilized Human SIRP alpha at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD47 protein. The ED_{50} for this effect is 388.5 ng/mL.
Appearance	Lyophilized powder
Formulation	Lyophilized after extensive dialysis against PBS or 10 mM Tris-Citrate, 150 mM NaCl, pH 8.0 or 20 mM PB, 150 mM NaCl, pH 7.4.
Endotoxin Level	<1 EU/μg, determined by LAL method.
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH_2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background	Targeting CD47 is in the spotlight of cancer immunotherapy. Blocking CD47 triggers the recognition and elimination of cancer cells by the innate immunity. The CD47/SIRP-α axis has been established as an important regulator of innate anti-cancer immunity, with many if not all malignancies overexpressing the receptor CD47 that binds to phagocyte-expressed SIRP-α[1].

REFERENCES

[1]. Huang Y, et al. Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. J Thorac Dis. 2017 Feb;9(2):E168-E174.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA